Rabbit Polyclonal CLDN10 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01814(SLPI Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of CLDN10 Antibody**

Claudin-10 (CLDN10), a member of the claudin family, is a critical component of tight junctions—specialized protein complexes that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial tissues. The CLDN10 gene encodes two major isoforms, CLDN10a and CLDN10b, generated via alternative promoter usage. These isoforms exhibit distinct tissue-specific expression patterns and functional roles. CLDN10a is predominantly expressed in the kidney (e.g., thick ascending limb of Henle’s loop) and contributes to ion-selective paracellular transport, particularly for Cl⁻ ions. In contrast, CLDN10b is found in tissues like the liver and pancreas and is associated with Na⁺ permeability.

CLDN10 antibodies are essential tools for studying the localization, expression, and function of CLDN10 in health and disease. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate tight junction dynamics in conditions like renal disorders, cancer, or skin diseases. Dysregulation of CLDN10 has been linked to electrolyte imbalances, polyuria, and pathological remodeling of epithelial barriers. Additionally, CLDN10 antibodies aid in exploring isoform-specific roles, as genetic knockout models suggest CLDN10’s involvement in systemic homeostasis and organ development.

Commercial CLDN10 antibodies are typically raised against peptide sequences unique to specific isoforms, ensuring target specificity. Validation steps, including knockout controls and tissue staining patterns, are critical to confirm antibody reliability. Research on CLDN10 continues to expand, driven by its potential as a therapeutic target or biomarker for epithelial barrier-related pathologies.